A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

PURPOSE: Clostridium difficile infection (CDI) represents a significant economic healthcare burden, especially the cost of recurrent disease. Fidaxomicin produced significantly lower recurrence rates and higher sustained cure rates in clinical trials. We evaluated the cost-effectiveness and budget i...

Descripción completa

Detalles Bibliográficos
Autores principales: Watt, Maureen, McCrea, Charles, Johal, Sukhvinder, Posnett, John, Nazir, Jameel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042976/
https://www.ncbi.nlm.nih.gov/pubmed/27062378
http://dx.doi.org/10.1007/s15010-016-0894-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042976/
https://www.ncbi.nlm.nih.gov/pubmed/27062378
http://dx.doi.org/10.1007/s15010-016-0894-y

Ejemplares similares